Advertisement

Accessory pathway location affects brain natriuretic peptide level in patients with Wolff–Parkinson–White syndrome

  • Yosuke Nakatani
  • Koji Kumagai
  • Shigeto Naito
  • Kohki Nakamura
  • Kentaro Minami
  • Masahiro Nakano
  • Takehito Sasaki
  • Koichiro Kinugawa
  • Shigeru Oshima
Article

Abstract

Purpose

The purpose of this study was to investigate the relationship between the accessory pathway location and brain natriuretic peptide (BNP) level in patients with Wolff–Parkinson–White (WPW) syndrome.

Methods

We divided 102 WPW syndrome patients with normal left ventricular systolic function into four groups: those with manifest right (MR, n = 14), manifest septal (MS, n = 11), manifest left (ML, n = 30), and concealed (C, n = 47) accessory pathways. BNP level and electrophysiological properties, including difference in timing of the ventricular electrogram between the His bundle area and the distal coronary sinus area (His–CS delay), which indicate intraventricular dyssynchrony, were compared.

Results

BNP levels (pg/dl) were higher in the MR and MS groups than in the ML and C groups (MR, 64 ± 58; MS, 55 ± 45; ML, 17 ± 15; C, 25 ± 21; P < 0.001). AV intervals (ms) were shorter in the MR and MS groups than in the ML and C groups (MR, 76 ± 16; MS, 83 ± 6; ML, 101 ± 19; C, 136 ± 20; P < 0.001). His–CS delay (ms) was longer in the MR group than in the other groups (MR, 50 ± 15; MS, 21 ± 7; ML, 23 ± 10; C, 19 ± 8; P < 0.001). The AV interval (P < 0.01) and the His–CS delay (P < 0.001) were negatively and positively correlated, respectively, with the BNP level.

Conclusion

Anterograde conduction with a right or septal accessory pathway increased the BNP level in WPW syndrome patients with normal cardiac function.

Keywords

Wolff–Parkinson–White syndrome Brain natriuretic peptide Accessory pathway Cardiac dyssynchrony 

Notes

Acknowledgments

This research received no grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This study was not funded.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

References

  1. 1.
    Hishida H, Sotobata I, Koike Y, Okumura M, Mizuno Y. Echocardiographic patterns of ventricular contraction in the Wolff-Parkinson-White syndrome. Circulation. 1976;54:567–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Chandra MS, Kerber RE, Brown DD, Funk DC. Echocardiography in Wolff-Parkinson-White syndrome. Circulation. 1976;53:943–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Francis GS, Theroux P, O’Rourke RA, Hagan AD, Johnson AD. An echocardiographic study of interventricular septal motion in the Wolff-Parkinson-White syndrome. Circulation. 1976;54:174–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Tomaske M, Janousek J, Rázek V, Gebauer RA, Tomek V, Hindricks G, et al. Adverse effects of Wolff-Parkinson-White syndrome with right septal or posteroseptal accessory pathways on cardiac function. Europace. 2008;10:181–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Kwon BS, Bae EJ, Kim GB, Noh CI, Choi JY, Yun YS. Septal dyskinesia and global left ventricular dysfunction in pediatric Wolff-Parkinson-White syndrome with septal accessory pathway. J Cardiovasc Electrophysiol. 2010;21:290–5.CrossRefPubMedGoogle Scholar
  6. 6.
    De Boeck BW, Teske AJ, Leenders GE, Mohamed Hoesein FA, Loh P, van Driel VJ, et al. Detection and quantification by deformation imaging of the functional impact of septal compared to free wall preexcitation in the Wolff-Parkinson-White syndrome. Am J Cardiol. 2010;106:539–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Park HE, Chang SA, Kim JH, Oh IY, Choi EK, Oh S. Left ventricular dyssynchrony in pre-excitation syndrome: effect of accessory pathway location and reversibility after ablation therapy. Heart Vessels. 2013;28:199–207.CrossRefPubMedGoogle Scholar
  8. 8.
    Udink ten Cate FE, Kruessell MA, Wagner K, Trieschmann U, Emmel M, Brockmeier K, et al. Dilated cardiomyopathy in children with ventricular preexcitation: the location of the accessory pathway is predictive of this association. J Electrocardiol. 2010;43:146–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Fukunaga H, Akimoto K, Furukawa T, Takahashi K, Kishiro M, Shimizu T, et al. Improvement in non-tachycardia-induced cardiac failure after radiofrequency catheter ablation in a child with a right-sided accessory pathway. Heart Vessels. 2013;28:802–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Fujii J, Wantanabe H, Watanabe T, Takahashi N, Ohta A, Kato K. M-mode and cross-sectional echocardiographic study of the left ventricular wall motions in complete left bundle-branch block. Br Heart J. 1979;42(3):255–60.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep. 2000;2:198–205.CrossRefPubMedGoogle Scholar
  13. 13.
    Ohba H, Takada H, Musha H, Nagashima J, Mori N, Awaya T, et al. Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. Am Heart J. 2001;141:751–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Cosío FG, Anderson RH, Kuck KH, Becker A, Borggrefe M, Campbell RW, et al. Living anatomy of the atrioventricular junctions. A guide to electrophysiologic mapping. A Consensus Statement from the Cardiac Nomenclature Study Group, Working Group of Arrhythmias, European Society of Cardiology, and the Task Force on Cardiac Nomenclature from NASPE. Circulation. 1999;100:e31–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Pitzalis MV, Iacoviello M, Romito R, Guida P, De Tommasi E, Luzzi G, et al. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. J Am Coll Cardiol. 2005;45:65–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Tulevski II, Groenink M, van Der Wall EE, van Veldhuisen DJ, Boomsma F, Stoker J, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart. 2001;86:27–30.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–82.CrossRefPubMedGoogle Scholar
  18. 18.
    Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol. 2006;47:85–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev. 2007;12:23–36.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47:582–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-Type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46:610–20.CrossRefPubMedGoogle Scholar
  22. 22.
    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation. 2014;130:811–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Bunch TJ, May HT, Bair TL, Anderson JL, Crandall BG, Cutler MJ, et al. Long-term natural history of adult Wolff-Parkinson-White syndrome patients treated with and without catheter ablation. Circ Arrhythm Electrophysiol. 2015;8:1465–71.PubMedGoogle Scholar
  25. 25.
    Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American Academy of Pediatrics (AAP), Canadian Heart Rhythm Society (CHRS), et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm. 2012;9:1006–24.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Second Department of Internal MedicineUniversity of ToyamaToyamaJapan
  2. 2.Division of CardiologyGunma Prefectural Cardiovascular CenterGunmaJapan

Personalised recommendations